US Edition
Trump administration drops Biden plan for Medicare to cover weight-loss drugs
- The Trump administration has decided not to cover obesity medications under Medicare's Part D, as reported by the Centers for Medicare and Medicaid Services.
- Biden proposed a rule to include coverage for medications like Zepbound and Wegovy, but the rule is not implemented yet.
- Polling indicates about 40% of U.S. adults support Medicare and Medicaid covering weight-loss drugs, with concerns about costs and side effects raised by health policy organizations.
- States that provide coverage for GLP-1 drugs are managing costs by implementing prescribing limits and meeting certain patient criteria.
298 Articles
298 Articles
Trump scraps Biden’s plan to cover Wegovy and Zepbound through Medicare
President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government’s Medicare program.The Centers for Medicare and Medicaid Services said late Friday that it would not cover the medications under Medicare’s Part D prescription drug coverage. Medicare covers health care expenses mainly for people age 65 and older.Trump’s predecessor, Joe Biden, proposed a rule in late November a…
The Avery Journal-Times
Biden Plan To Expand Obesity Drug Coverage Is Rejected
Key Takeaways
Commentary: Rural Americans Need the Trump Administration to Provide an Additional Path to Fight Obesity
I spent over seven hours in the car driving one way to my most recent doctor’s appointment. For many Americans, this may be shocking, but for those of us who live in rural areas, it’s a way of life. Far too often rural Americans have been left behind by our healthcare system. This is especially true for those of us living with obesity, which impacts many Americans in rural regions of the country. As the Trump administration sets out to make Amer…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
